Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
Patient took the second dose of Vivotif vaccine four hours after meal; Case reference number US-BN-2024-001907 is a spontaneous case report initially received from a consumer (self-report) via Med Communications (reference number: USBAV24-1029) on 14-May-2024 and concerns a patient of unspecified age or gender. The patient's relevant medical history and concomitant medications were not provided. On unspecified date, patient took the first dose of Vivotif (batch number: unknown), at unknown dose or route of administration, for unknown indication. On unspecified date, reported as on alternate day, the patient took the second dose of Vivotif (batch number: unknown), at unknown dose or route of administration. As reported, the patient took the second dose of Vivotif four hours after meal (explicitly coded as 'product administration error') At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information provided.; Reporter's Comments: A patient of unspecified age or gender took the second dose of Vivotif for unknown indication four hours after the meal, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unspecified age or gender took the second dose of Vivotif for unknown indication four hours after the meal, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None